Skip to main content

Table 3 Assessment of efficacy and safety based on laboratory data (the long-term continual use group)

From: A laboratory data-based evaluation of the efficacy and safety of generic pravastatin sodium for long-term use

  Short-term treatment Long-term treatment  
Plasma parameter Mean ± S.D. N Mean ± S.D. N p-value
TC 195 ± 25.0 407 196 ± 28.5 417 0.42
TG 129 ± 76.8 405 123 ± 65.5 449 0.16
HDL-C 60.8 ± 15.6 388 61.9 ± 16.6 437 0.32
LDL-C 109 ± 20.1 239 112 ± 24.0 246 0.06
AST 24.2 ± 12.2 419 23.2 ± 9.29 473 0.19
ALT 23.1 ± 21.6 418 20.4 ± 11.3 473 0.02
CPK 112 ± 86.5 358 108 ± 67.9 395 0.51
γ-GTP 35.3 ± 52.4 324 33.0 ± 35.5 385 0.50
ALP 236 ± 72.1 266 245 ± 81.8 286 0.18
T-Bil 0.66 ± 0.25 242 0.67 ± 0.27 303 0.91
LDH 198 ± 37.4 372 196 ± 39.1 417 0.48
BUN 17.0 ± 8.78 384 17.6 ± 8.39 461 0.27
Scr 0.87 ± 0.55 413 0.91 ± 0.74 478 0.40
HbA1c 6.26 ± 0.83 308 6.24 ± 0.88 341 0.87
  1. Total plasma cholesterol, TC; triglyceride, TG; high-density lipoprotein cholesterol, HDL-C; low-density lipoprotein cholesterol, LDL-C; aspartate aminotransferase, AST; alanine aminotransferase, ALT; creatine phosphokinase, CPK; gamma-glutamyl transferase, γ-GTP; alkaline phosphatase, ALP; lactate dehydrogenase, LDH; total bilirubin, T-Bil; blood urea nitrogen, BUN; serum creatinine, Scr; hemoglobin A1c, HbA1c; standard deviation, S.D